Skip to Main Content

Mark Schoenebaum was a brilliant and successful Wall Street research analyst who fundamentally changed the way sell-siders cover biotech stocks. More importantly, Mark was a remarkably nice guy. Wall Street is not known for warm and fuzzy people, but Mark smashed that mold. He was kind and funny. He was gregarious and uncommonly generous to colleagues, friends, and even strangers.

Most of the biotech investment community first heard about Mark’s death via a gut-wrenching email sent by his friend and former colleague Umer Raffat on Sunday evening.


“We’ve all looked up to him as the very best equity research analyst there has ever been on Wall Street,” Raffat wrote. “But that was only part of who he was: he was an absolute standout individual who touched so many lives, and whose strength of character showed in his sheer humility despite his absolutely unprecedented success.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.